D-
Advancing Phase 1b/2a trial for WVE-003 (SNP3) program in HD; WVE-003 uses new PN backbone chemistry modifications, which demonstrate improved preclinical pharmacology. Wave expects to initiate dosing in a Phase 1b/2a clinical trial for WVE-003 in 2021.
Best,
G
Disclosure: I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.
Notice: This post is not investment advice, and not a recommendation to neither buy nor hold nor sell.